鼻窦癌生存者照护的现状
鼻窦癌是组织学异质的罕见病,晚期标准治疗为手术联合化疗和/或放疗,但监测与随访指南及正式生存者照护路径很少。本文通过范围综述检索PubMed、EMBASE和Google Scholar,纳入112项研究,按监测、第二原发肿瘤、生活质量和症状负担分组。鼻窦癌局部失败率较高且发生较晚,失败部位和复发风险随时间变化具有组织学特异性;多模式治疗后患者可能出现内分泌、视觉、听觉、鼻窦、嗅觉和神经认知缺陷及心理社会损害,生活质量下降。
要点
- 鼻窦癌组织学异质,局部失败率较高且发生较晚,失败部位和复发风险具组织学特异性。
- 颅底多模式治疗后可能出现内分泌、视觉、听觉、鼻窦、嗅觉和神经认知缺陷及心理社会损害。
- 患者可能受益于针对复发、第二原发肿瘤和治疗毒性的组织学特异性生存者照护项目。
核心结论
- 鼻窦癌患者可能受益于量身定制的、组织学特异性的生存者照护项目,以应对疾病和治疗毒性导致的复发、第二原发肿瘤和功能损害。
研究设计与样本
- 范围综述,通过PubMed、EMBASE和Google Scholar检索,共纳入112项研究。
主要发现
- 纳入研究按监测、第二原发肿瘤、生活质量和症状负担分组。
- 鼻窦癌与头颈部黏膜恶性肿瘤相比,局部失败率较高且发生较晚。
- 失败部位和随时间变化的复发风险具有组织学特异性。
- 颅底多模式治疗后患者可能出现内分泌、视觉、听觉、鼻窦、嗅觉和神经认知缺陷,以及心理社会损害,影响多个身体和神经心理领域,导致生活质量下降。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sinonasal cancer is a heterogeneous orphan disease of diverse histologies, each with distinct clinical, oncologic, and toxicity profiles. Because of the comparative rarity of these cancers, sinonasal cancers are treated as a grouped diagnosis despite their clinical and biological heterogeneity. Multimodality treatment with a combination of surgery, chemotherapy, and/or radiotherapy is the standard-of-care for advanced-stage patients but there are few surveillance or follow-up practice guidelines or formalized survivorship care pathways. A scoping literature review was conducted via PubMed, EMBASE, and Google Scholar. A total of 112 studies were included, which were grouped along the following topics: surveillance, second primary tumors, quality of life, and symptom burden. Sinonasal cancer tends to exhibit a higher rate of local failure and occur in a delayed fashion compared to mucosal malignancies of the head and neck. Moreover, the site of failure and time-varying risk of recurrence is histology-specific. Following multimodality treatment of the skull base, patients may experience endocrine, visual, auditory, sinonasal, olfactory, and neurocognitive deficits, as well as psychosocial impairments that impact multiple physical and neuropsychological domains, resulting in diminished quality of life. Sinonasal cancer patients would benefit from tailored, histology-specific survivorship programs to address the recurrence, second primary, and functional impairments resulting from disease and treatment toxicity.
引用
- Han AY, Nader ME, Lam K, et al. Current status of sinonasal cancer survivorship care. Head Neck. 2023. PMID: 37449544. doi:10.1002/hed.27457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。